biosensis fine bioscience tools - antibodies, elisa kits, proteins, toxins and peptides An Australia-US partnershipPhone: 1800 605 5127 in the US, or +61 8 8352 7711 for international enquiries to Australia.
HomeAbout BiosensisBiosensis distributorsResourcesHelp deskordering from BiosensisContact usFlyers

Technical Notes
View our tech notes
Follow us...
Google+ Follow us on Twitter

Find us on Facebook

Sign up for Biosensis newsletters
Visit our newsletter archive
News and Site Information.

FDA endorses biomarker for AD


More and more research is emerging about the importance of the oligomeric form of Amyloid Beta peptide (Aβ,1-42) and its close link to Alzheimer's Disease.

In the recent paper published by Bode DC, et al. (Dec 2016), it mentions "Alzheimer's disease (AD) is the most prevalent fatal neurodegenerative disease worldwide and accounts for up to 80% of all dementia cases." You can read the full paper here.

Biomarkers are urgently needed to assist clinical trials for the treatment of Alzheimer's Disease. The FDA have also supported this claim by releasing a 'Biomarker Letter of Support' to "encourage further study and use of CSF analytes Aβ1-42, total Tau, and phosphotau, as exploratory prognostic biomarkers for enrichment in trials for Alzheimer's Disease (AD)." The full contents of the Letter can be seen here.

Biosensis has released a research-use-only Oligomeric Amyloid beta ELISA Kit that is aimed at assisting researchers with their Biomarker research. We are committed to supplying the best quality life science products to the research community.

Biosensis' Oligomeric Amyloid beta (oAβ) ELISA Kit (Catalog No: BEK-2215-1P) is built upon the anti-amyloid beta monoclonal MOAB-2 (Catalog No: M-1586-100). The Biosensis MOAB-2 antibody has been shown to specifically detect Aβ, but not the precursor molecule AP.

This is the first oligomeric amyloid beta ELISA to take advantage of MOAB-2's high specificity and avidity for beta amyloid peptides and combine it in a proprietary formulation that allows for the detection of amyloid beta oligomers and complexes present in mouse and human CSF and brain tissue extracts.

Biosensis' Oligomeric Aβ ELISA has recently been published in these significant papers:
    •    Cacciottolo M, et al. (2017) Particulate air pollutants, APOE alleles and their contributions to cognitive impairment in older women and to amyloidogenesis in experimental models. Translational Psychiatry. 7(1):e1022. PMID: 28140404. Species: EFAD transgenic mice.
    •    Peng W, et al. (2016) Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease. Neurobiology of disease. 93:215-25. PMID: 27234656. Species: TBSX-extracts of mouse cerebral cortex.
    •    Seo Dong Han, et al. (2015) Plasma-enabled sustainable elemental lifecycles: honeycomb-derived graphenes for next-generation biosensors and supercapacitors. Green Chem. 17, 2164-2171. Species: Synthetic constructs.
    •    Combes M, et al. (2014) Glutamate protects neuromuscular junctions from deleterious effects of β-amyloid peptide and conversely: An in vitro study in a nerve-muscle coculture. J Neurosci Res. 93(4):633-43. PMID: 25491262. Species: Rat neurites & human muscle cell co-culture supernatants.
    •    Liu Y, et al. (2014) IKKbeta Deficiency in Myeloid Cells Ameliorates Alzheimer's Disease-Related Symptoms and Pathology. J Neurosci. 34(39):12982-99. PMID: 25253847. Species: Transgenic Mouse brain lysates.
    •    Tai LM, et al. (2014) Amyloid-β Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in vivo. J Biol Chem. 289(44):30538-55. PMID: 25217640. Species: EFAD-Tg mice.

Biosensis has also used the MOAB-2 antibody in the development of our Aβ/APOE ELISA (Catalog No: BEK-2224-1P).